PoliticalRepoPoliticalRepo

Bill · HR

H.R. 8205 (119th)

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Original

openUnited States· United States Congress· EN

Introduced

6 April 2026

Last action

23 July 2026 · Introduced

Status

Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.

Sponsors

Mike Quigley, Rep. Calvert, Ken [R-CA-41], Rep. Fitzpatrick, Brian K. [R-PA-1], Janice Schakowsky, Rep. McCaul, Michael T. [R-TX-10], Jake Auchincloss, Scott DesJarlais, Angie Craig, David Valadao, Jason Crow, Glenn Thompson, Rep. Moore, Gwen [D-WI-4], Jeff Hurd, Bradley Schneider, David Joyce, Marc Veasey, Maria Salazar, Suzanne Bonamici, Rep. Bilirakis, Gus M. [R-FL-12], Brad Sherman, Andrew Garbarino, Stephen Lynch, Rep. Bacon, Don [R-NE-2], Steve Cohen, Pete Sessions, Adam Smith, Jay Obernolte, Madeleine Dean, Tom Cole, Valerie Foushee, John Rutherford, Terri Sewell, Joe Wilson, Danny Davis, Rep. Aderholt, Robert B. [R-AL-4], Ritchie Torres, Rep. Mann, Tracey [R-KS-1], Del. Norton, Eleanor Holmes [D-DC-At Large], Jefferson Van Drew, Raja Krishnamoorthi, Mark Alford, Lauren Underwood, Rep. LaLota, Nick [R-NY-1], Kim Schrier, Young Kim, Doris Matsui, Rep. Edwards, Chuck [R-NC-11], Debbie Dingell, Rep. Walberg, Tim [R-MI-5], Rashida Tlaib, Rep. Weber, Randy K. Sr. [R-TX-14], Mike Thompson, Rep. Bost, Mike [R-IL-12], Paul Tonko, Stephanie Bice, Suzan DelBene, Mario Diaz-Balart, J. Correa, Darin LaHood, Timothy Kennedy, Steve Womack, George Whitesides, David Rouzer, Sanford Bishop, Julia Letlow, Robin Kelly, Mark Amodei, Rep. Gottheimer, Josh [D-NJ-5], Tim Moore, Emanuel Cleaver, John Carter, Greg Stanton, Rep. Wittman, Robert J. [R-VA-1], Rep. Vindman, Eugene Simon [D-VA-7], Rep. Guest, Michael [R-MS-3], Janelle Bynum, Rep. Miller, Carol D. [R-WV-1], Jahana Hayes, George Latimer, Donald Davis, Sarah McBride, Josh Riley, Herbert Conaway, Melanie Stansbury, Deborah Ross, Chellie Pingree, James Himes, Bonnie Watson Coleman, Sean Casten, Rep. Landsman, Greg [D-OH-1], Adelita Grijalva, Analilia Mejia, Rep. Larson, John B. [D-CT-1], Eric Sorensen, Scott Peters, Jonathan Jackson, Alma Adams, Nikki Budzinski, Joyce Beatty, Seth Magaziner, Marcy Kaptur, Troy Carter, Rep. Suozzi, Thomas R. [D-NY-3], Mary Gay Scanlon

Subjects

Healthcare

Source updated

20 August 2026

Healthcare

Official sourceDownload fileView documentsShare

Summary

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases.  Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

  1. 6 April 2026

    Referred

    Referred to the Subcommittee on Health.

    Source: Committee

  2. 6 April 2026

    Introduced

    Referred to the House Committee on Energy and Commerce.

    Source: IntroReferral

  3. 6 April 2026

    Introduced

    Introduced in House

    Source: IntroReferral

  4. 6 April 2026

    Introduced

    Introduced in House

    Source: IntroReferral

  5. 13 May 2026

    Committee

    Forwarded by Subcommittee to Full Committee by Voice Vote.

    Source: Committee

  6. 13 May 2026

    Committee

    Subcommittee Consideration and Mark-up Session Held

    Source: Committee

  7. 21 May 2026

    Vote

    Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.

    Source: Committee

  8. 21 May 2026

    Committee

    Committee Consideration and Mark-up Session Held

    Source: Committee

  9. 9 July 2026

    Calendars

    Placed on the Union Calendar, Calendar No. 637.

    Source: Calendars

  10. 9 July 2026

    Reported

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

    Source: Committee

  11. 9 July 2026

    Reported

    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.

    Source: Committee

  12. 20 July 2026

    Floor

    DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.

    Source: Floor

  13. 20 July 2026

    Floor

    Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)

    Source: Floor

  14. 20 July 2026

    Floor

    Mr. Guthrie moved to suspend the rules and pass the bill, as amended.

    Source: Floor

  15. 20 July 2026

    Floor

    At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.

    Source: Floor

  16. 22 July 2026

    Passed

    Motion to reconsider laid on the table Agreed to without objection.

    Source: Floor

  17. 22 July 2026

    Passed

    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

    Source: Floor

  18. 22 July 2026

    Passed

    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.

    Source: Floor

  19. 22 July 2026

    Floor

    Considered as unfinished business. (consideration: CR H5159)

    Source: Floor

  20. 23 July 2026

    Introduced

    Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.

    Source: Calendars

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

5 official files

Sponsors

Related records

Sources

PoliticalRepo is an index and interpretation layer, not the authoritative legal source.